Risk topic

Labor and talent

217 of 1505 companies added a paragraph in Risk Factors that uses one of these words: labor shortage, labor union, labor unions, unionized, collective bargaining, key personnel, attract and retain. The paragraph is in the latest 10-K and nothing like it was in the one before. It counts text; it does not say how serious a risk is. Words in capitals only (such as AI) must be in capitals.

By sector

Sector is the SEC's industry description of the company. The bar is the share of that sector's companies compared; each count opens that sector's quotes below.

304 paragraphs · Electromedical & Electrotherapeutic Apparatus show all sectors

LIVN LivaNova PLC · Electromedical & Electrotherapeutic Apparatus

LivaNova operates in a highly competitive market characterized by increasingly complex products that are expensive and time-consuming to develop and manufacture. The Company’s success depends on several factors, including its ability to appropriately allocate the Company’s R&D resources, integrate advanced software and AI capabilities, attract and retain key talent, achieve market adoption of its technologies, and sustain innovation. In the product lines in which LivaNova competes,

Read in the 10-K filed Feb 25, 2026

Responding to such actions could require significant time and attention from LivaNova’s Board of Directors and management, result in substantial legal and advisory expenses, and disrupt the Company’s operations. Actual or perceived uncertainty regarding the Company’s strategic direction or leadership arising from activist campaigns could adversely affect the Company’s relationships with customers, suppliers, employees, and other stakeholders; create volatility in the share price; and impact the Company’s ability to attract and retain qualified personnel and business partners.

Read in the 10-K filed Feb 25, 2026
TMDX TransMedics Group, Inc. · Electromedical & Electrotherapeutic Apparatus

Product development and regulatory activities depend on the continuity and capacity of the FDA and other health authorities. Disruptions at the FDA and other agencies may slow the time necessary for new products to be reviewed and/or approved by necessary government agencies, which could adversely affect our business. The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in the past as a result. In addition, government funding of the FDA and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. If there are future shutdowns, our business, financial condition, operating results, cash flows or prospects could be adversely affected.

Read in the 10-K filed Feb 24, 2026
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.